logo

For the Inventor, By the Inventor

Campbell, CA, United States of America

Peter Brams

This inventor holds 24 USPTO granted patents, primarily in Antibody Therapeutics. Top assignees: Biogen Idec, Inc., Idec Pharmaceuticals Corporation, Lidak Pharmaceuticals. Active years: 1997-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Brams. Retrieved from https://idiyas.com/inventor/peter-brams-oxe5anj2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24

% Patents Active = 54.2

Average Co-Inventor Count = 3.0

ph-index = 11

Forward Citations = 627(Granted Patents)


Location History:

  • Guttenberg, NJ (US) (1997)
  • San Diego, CA (US) (1998 - 2008)
  • Campbell, CA (US) (2008 - 2009)

Company Filing History:

goldMedal12 out of 46 
 
Biogen Idec, Inc.
 patents
silverMedal8 out of 37 
 
Idec Pharmaceuticals Corporation
 patents
bronzeMedal1 out of 9 
 
Lidak Pharmaceuticals
 patents
4. 1 out of 1 
 
Xenerex Biosciences
 patent
5. 3 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2009

Loading Chart...
Areas of Expertise:
CD80-Specific Antibodies
Immunosuppression
B Cell Lymphoma
Rheumatoid Arthritis
Anti-CD80 Antibodies
Nucleic Acids
Human Monoclonal Antibodies
SCID Mice
Psoriasis Treatment
Intestinal Inflammation
RSV F-Protein
Transfectomas
24 patents (USPTO):Explore Patents
1. 7510713 - Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies (2009-03-31),
2. 7510712 - Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies (2009-03-31),
3. 7501264 - Methods of producing 7C10 and 16C10 CD80-specific antibodies (2009-03-10),
4. 7491393 - Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies (2009-02-17),
5. 7425447 - Host cells expressing 7C10 and 16C10 CD80-specific antibodies (2008-09-16),
6. 7417128 - 7C10 and 16C10 CD80-specific antibodies (2008-08-26),
7. 7414123 - Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies (2008-08-19),
8. 7323170 - Anti-CD80 antibodies (2008-01-29),
9. 7192585 - CD80 specific antibodies (2007-03-20),
10. 7175847 - Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 (2007-02-13),
11. 7153508 - Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 (2006-12-26),
12. 7118924 - Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents (2006-10-10),
13. 6893638 - Methods for treating b cell lymphoma using CD80-specific antibodies (2005-05-17),
14. 6709654 - Treatment of psoriasis using anti-B7.1 (CD80) antibodies (2004-03-23),
15. 6537809 - Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof (2003-03-25),

Title: The Inventor Peter Brams: Pioneering Innovations in Campbell, CA

Introduction: Peter Brams is a distinguished inventor based in Campbell, CA, known for his groundbreaking contributions to various fields.

Latest Patents: Peter Brams holds several patents in the areas of technology and healthcare, showcasing his continuous commitment to innovation.

Career Highlights: With a career spanning over two decades, Peter Brams has worked on numerous projects that have revolutionized the industry, earning him a reputation as a visionary inventor.

Collaborations: Throughout his career, Peter Brams has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Peter Brams' passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors, making him a true pioneer in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…